Floatz logo

Blinatumomab

Philadelphia Chromosome Positive

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the Philadelphia Chromosome Positive cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 3BB
Cytosin-Arabinosid
M.D. Anderson Cancer Center
Phase 3BB
DEXAMETHASONE
M.D. Anderson Cancer Center
Phase 3BB
VINCRISTINE SULFATE
M.D. Anderson Cancer Center
Phase 3BB
Inno-206
M.D. Anderson Cancer Center
Phase 3BB

View all 28 →

Same molecule, other indications

Blinatumomab is also rated in:

precursor B-cell acute lymphoblastic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BBB
Indicative ·
72 / 100
View asset →
Precursor B-Cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →